Considering the suppression of hPD-L1 MC38 tumor growth by RGE in in vitro, in vivo, and co-culture cell models, and the activation of tumor-infiltrating CD8+ T cells by RGE treatment, we examined CD8+ T cell infiltration into hPD-L1 MC38 tumor tissues following RGE or Keytruda treatment. The gene discussed is CD8A; the disease is neoplasm.